Stay updated on Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial

Sign up to get notified when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was implemented and the government operating-status notice was removed.
    Difference
    0.4%
    Check dated 2026-02-11T14:22:56.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Administrative updates were added: a government funding notice about NIH status and a new Revision: v3.4.1 replacing v3.4.0; these updates do not affect study details or enrollment information. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-04T10:25:51.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page adds a glossary toggle and updates metadata labels to 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and the revision note to 'Revision: v3.4.0', replacing the previous wording. These updates do not modify the study details or results.
    Difference
    0.2%
    Check dated 2026-01-28T05:01:15.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision string updated from v3.3.3 to v3.3.4 in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T02:32:32.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    A New York site was added under Locations, replacing the previous New York Locations entry. The HHS Vulnerability Disclosure link was removed from the footer, and the page shows Revision: v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T20:34:55.000Z thumbnail image
  7. Check
    91 days ago
    Change Detected
    Summary
    Revision updated from v3.2.0 to v3.3.2; no changes to core study details or user-facing information are apparent. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T14:15:41.000Z thumbnail image

Stay in the know with updates to Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.